Essex LLC Acquires New Shares in Danaher Corporation $DHR

Posted by Stanley Muller on Oct 14th, 2026

Essex LLC acquired a new stake in Danaher Corporation (NYSE:DHR – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,179 shares of the conglomerate’s stock, valued at approximately $4,692,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Marquette Asset Management LLC boosted its position in Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. Main Street Group LTD bought a new position in shares of Danaher during the first quarter worth about $25,000. Field & Main Bank acquired a new position in shares of Danaher in the 2nd quarter worth approximately $29,000. Finally, Evolution Wealth Management Inc. raised its position in shares of Danaher by 208.0% during the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 0.8%

Shares of DHR traded up $1.81 during midday trading on Wednesday, reaching $224.65. 3,595,884 shares of the stock were exchanged, compared to its average volume of 4,457,645. The company has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a P/E/G ratio of 2.78 and a beta of 0.76. The firm has a 50 day simple moving average of $212.41 and a 200-day simple moving average of $195.13. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the business earned $0.77 EPS. Danaher’s quarterly revenue was up 5.5% compared to the same quarter last year. Research analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on DHR. Stifel Nicolaus lowered their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Guggenheim boosted their price target on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus price target of $235.41.

View Our Latest Research Report on DHR

More Danaher News

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Danaher Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.